Identification and validation of a prognostic risk-scoring model based on sphingolipid metabolism-associated cluster in colon adenocarcinoma

Abstract

Colon adenocarcinoma (COAD) is the primary factor responsible for cancer-related mortalities in western countries, and its development and progression are affected by altered sphingolipid metabolism. The current study aimed at investigating the effects of sphingolipid metabolism-related (SLP) genes on multiple human cancers, especially on COAD. We obtained 1287 SLP genes from the GeneCard and MsigDb databases along with the public transcriptome data and the related clinical information. The univariate Cox regression analysis suggested that 26 SLP genes were substantially related to the prognosis of COAD, and a majority of SLP genes served as the risk genes for the tumor, insinuating a potential pathogenic effect of SLP in COAD development. Pan-cancer characterization of SLP genes summarized their expression traits, mutation traits, and methylation levels. Subsequently, we focused on the thorough research of COAD. With the help of unsupervised clustering, 1008 COAD patients were successfully divided into two distinct subtypes (C1 and C2). C1 subtype is characterized by a poor prognosis, activation of SLP pathways, high expression of SLP genes, disordered carcinogenic pathways, and immune microenvironment. Based on the clusters of SLP, we developed and validated a novel prognostic model, consisting of ANO1, C2CD4A, EEF1A2, GRP, HEYL, IGF1, LAMA2, LSAMP, RBP1, and TCEAL2, to quantitatively evaluate the clinical outcomes of COAD. The Kaplain-Meier survival curves and ROC curves highlighted the accuracy of our SLP model in both internal and external cohorts. Compared to normal colon tissues, expression of C2CD4A was detected to be significantly higher in COAD; whereas, expression levels of EEF1A2, IGF1, and TCEAL2 were detected to be significantly lower in COAD. Overall, our research emphasized the pathogenic role of SLP in COAD and found that targeting SLP might help improve the clinical outcomes of COAD. The risk model based on SLP metabolism provided a new horizon for prognosis assessment and customized patient intervention.

Association of the Advanced Lung Cancer Inflammation Index (ALI) and Gustave Roussy Immune (GRIm) score with immune checkpoint inhibitor efficacy in patients with gastrointestinal and lung cancer

“…Historical investigations have established a correlation between malnutrition and an unfavorable tumor prognosis [ 43 , 61 ]. Although diminished levels of albumin serve as an indicator of malnutrition, they concurrently function as a biomarker for systemic inflammation [ 62 – 64 ].…”

Prognostic nutritional index as a prognostic biomarker for gastrointestinal cancer patients treated with immune checkpoint inhibitors

“…In upper gastrointestinal cancer patients, nutritional problems are prevalent in up to 90% of cases, mainly due to reduced food intake and increased nutrition consumption by tumors (36). Long-standing research has linked malnutrition to a worse tumor prognosis (37,38). While low albumin levels are indicative of malnutrition, they can also serve as a biomarker for systemic FIGURE 4 Subgroup analysis of the relationship between prognostic nutritional index and overall survival based on the cut-off.…”

Identification and validation of neurotrophic factor-related gene signatures in glioblastoma and Parkinson’s disease

“…The “clusterProfiler” package of R software was used to carry out the functional enrichment analysis, which included KEGG and GO analysis ( 38 ). We adjusted the P values using the Benjamini - Hochberg (BH) technique.…”